4 results about "Cladribine" patented technology

The application belongs to the technical field of non-antibiotic compounds as bacteriostatic agents, and discloses an application of a known non-antibiotic compound, cladrabine, in inhibiting the growth of multi-drug resistant Klebsiella pneumoniae. The application finds that cladrabine can inhibit the growth of multi-drug resistant Klebsiella pneumoniae, and the minimum bacteriostatic concentration reaches 64 mg / L. Further exploration of the bacteriostatic mechanism finds that after exposure to cladrabine, the permeability of the bacterial cell membrane is enhanced, and the macromolecular substances (nucleic acids and proteins) in the cell are excreted, causing the integrity of the bacterial cell membrane to be destroyed, and further causing the death of Klebsiella pneumoniae. The application proposes that cladrabine can destroy the cell membrane of bacteria, change the permeability of the cell membrane, has a good inhibitory effect on multi-drug resistant Klebsiella pneumoniae, and can be further applied to the preparation of related drugs.

The application discloses a mucous membrane-adhesive polymeric microcarrier loaded with disodium cladribine tetrasodium and a preparation method and application thereof. Sodium alginate is modified by phenylboronic acid to obtain a PBA-Alg polymer; disodium cladribine tetrasodium is mixed with the polymer to obtain a precursor solution; microdroplets are formed by a microfluidic electrospray technology and sprayed into a calcium ion crosslinking solution to be solidified to obtain the microcarrier. In the microcarrier, the phenylboronic acid groups form reversible borate ester bonds with cis-diol groups in the disodium cladribine tetrasodium molecules, so that stable anchoring and continuous release of the drug are realized. The phenylboronic acid groups on the surface of the microcarrier can form dynamic covalent bonds with sialic acid residues in ocular surface mucin, so that long-acting adhesion on the ocular surface is realized; meanwhile, the borate ester bonds are oxidatively cleaved in the presence of excess active oxygen on the ocular surface, so that the active oxygen is consumed and inflammation is inhibited. The microcarrier has a highly uniform size and shear thinning characteristics, and can be safely, comfortably, efficiently and low-frequency used for the treatment of ocular surface diseases such as dry eye.